<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420355</url>
  </required_header>
  <id_info>
    <org_study_id>12637</org_study_id>
    <nct_id>NCT00420355</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients</brief_title>
  <official_title>The Pharmacokinetics of Lopinavir/Ritonavir in Combination With Atazanavir in HIV-Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the pharmacokinetics of lopinavir, ritonavir, and
      atazanavir when lopinavir/ritonavir and atazanavir are used in combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty patients with HIV infection will be enrolled in this open-label, parallel arm
      pharmacokinetic study. Subjects receiving either lopinavir/ritonavir or atazanavir/ritonavir
      as part of their antiretroviral therapy will have a pharmacokinetic study performed over
      12-20 days to examine whether coadministration of lopinavir and atazanavir alters the
      pharmacokinetics of either agent. The safety of these agents in combination will also be
      explored.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unexpected adverse event
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean pharmacokinetic parameters (Cmax, Cmin, AUC) for lopinavir, ritonavir, atazanavir</measure>
    <time_frame>Day 6, Day 12 or 16, Day 20</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (e.g., GI tolerance, lab abnormalities, ECG changes)</measure>
    <time_frame>Day 6, Day 12 or Day 16, Day 20</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on atazanavir/ritonavir will add lopinavir/ritonavir.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects on lopinavir/ritonavir will add atazanavir.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atazanavir</intervention_name>
    <description>Atazanavir 300 mg daily on Days 6-12.</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Reyataz 300 mg capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lopinavir/ritonavir</intervention_name>
    <description>Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Kaletra 200 mg/50 mg tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-seropositive

          -  Currently receiving atazanavir/ritonavir or lopinavir/ritonavir in combination with
             2-3 nucleoside RT inhibitors or are antiretroviral treatment-naïve

          -  If female, is not of childbearing potential or is of childbearing potential and agrees
             to use a barrier method of contraception throughout the study

        Exclusion Criteria:

          -  HIV-1 RNA &gt; 400 copies/mL if currently receiving antiretroviral therapy

          -  Concurrent use of CYP450 inhibitors or inducers

          -  Concurrent use of P-glycoprotein substrates, inhibitors, or inducers

          -  Concurrent use of medications known to interact with ritonavir or atazanavir

          -  Presence of a chronic health condition deemed by the investigators to potentially
             impair lopinavir, ritonavir, or atazanavir pharmacokinetics

          -  Presence of conduction abnormalities on electrocardiogram

          -  Women who are pregnant or breastfeeding

          -  Laboratory Abnormalities at baseline:

               -  Aminotransferases &gt; 3x ULN

               -  Serum bilirubin &gt; 5x ULN

               -  Serum creatinine &gt; 1.5x ULN

               -  Hemoglobin concentration &lt; 8.0 g/dL

               -  Absolute neutrophil count &lt; 800 cells/μL

               -  Platelet count &lt; 50,000 cells/μL
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R. Chris Rathbun, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oklahoma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OUHSC General Clinical Research Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <last_update_submitted>February 5, 2009</last_update_submitted>
  <last_update_submitted_qc>February 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>R. Chris Rathbun, Pharm.D.</name_title>
    <organization>University of Oklahoma Health Sciences Center</organization>
  </responsible_party>
  <keyword>antiretroviral therapy</keyword>
  <keyword>protease inhibitors</keyword>
  <keyword>drug interactions</keyword>
  <keyword>HIV infection</keyword>
  <keyword>acquired immunodeficiency syndrome</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

